More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment

https://investor.myriad.com/news-releases/news-release-detail/11351/

Newly Published Study Finds High Prevalence of BRCA Mutations ...

... BRCA1/2 mutation. When a family history of breast and/or ovarian cancer are also present, testing women with early-onset CIS may increase the likelihood of ...

https://investor.myriad.com/news-releases/news-release-detail/?newsItemId...

Myriad Receives FDA Approval of BRACAnalysis CDx® as a ...

May 20, 2020 ... BRACAnalysis CDx is the only FDA-approved germline test to identify men with BRCA1 and BRCA2 mutations, a subpopulation of HRR gene mutations.

https://investor.myriad.com/news-releases/news-release-detail/27171/

Myriad Genetics Expands Access for MyChoice Test to Prostate ...

1 day ago ... ... BRCA1/2 status for breast and prostate cancers. “Expanding the MyChoice test into prostate cancer marks an important milestone for Myriad ...

https://investor.myriad.com/news-releases/news-release-detail/24686/

Myriad Genetics Applauds New Germline Testing Guideline for ...

Jan 9, 2024 ... ... BRCA1/2 testing. All patients with a current or previous diagnosis of invasive breast cancer > 65 years should be offered BRCA1/2 testing if ...

https://investor.myriad.com/news-releases/news-release-detail/11401/

New Study Published in CANCER Supports Use of BRACAnalysis ...

Apr 30, 2009 ... (NASDAQ: MYGN) announced today that an article entitled "BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for ...

https://investor.myriad.com/news-releases/news-release-detail/12041/

Myriad myRisk® Hereditary Cancer Article in Journal of Clinical ...

Mar 30, 2016 ... "This is the first study to show the frequency of germline mutations in BRCA1/2 and other breast cancer predisposition genes in a sequential ...

https://investor.myriad.com/news-releases/news-release-detail/?newsItemId...

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as ...

Mar 11, 2022 ... More patients with breast cancer now potentially qualify for BRCA testing.” BRACAnalysis CDx is intended to detect and interpret germline BRCA1 ...

https://investor.myriad.com/news-releases/news-release-detail/12186/

Myriad Announces Four Poster Presentations at the 2016 European ...

Title: Outcomes of clinical testing for tumor BRCA1 and BRCA2 gene analysis for 354 patients: First experience with tumor companion diagnostic for PARP ...

https://investor.myriad.com/news-releases/news-release-detail/11856/

Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ...

May 29, 2015 ... Myriad myRisk Finds >60 Percent More Mutations Than BRCA1/2 Testing in Multiple Studies.

https://investor.myriad.com/news-releases/news-release-detail/11646/

Myriad Publishes myRisk Hereditary Cancer Study in Cancer

Sep 3, 2014 ... ... BRCA1/2 testing, and 377 patients with a personal and family history who previously tested negative for BRCA mutations. Deleterious ...